Literature DB >> 19717093

30 years and a long way into p53 research.

Pierre Hainaut1, Klas G Wiman.   

Abstract

Among the 278,092 publications indexed into PubMed in 1979, a handful of articles stand out as the foundation of one of the most profound forays into the molecular basis of carcinogenesis: the discovery of the p53 tumour-suppressor protein. In the 30 years since then, understanding of p53 has progressed from obscure oncogene to key tumour-suppressor gene with clinical potential. Yet, p53 research has not followed a straight course. In this Historical Review, we describe how the 1979 discovery has shaped our view of the molecular basis of cancer, and identify some crucial steps ahead to transfer the wealth of knowledge accumulated on p53 into applications to cancer prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717093     DOI: 10.1016/S1470-2045(09)70198-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  31 in total

1.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

2.  A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes.

Authors:  Adam Shlien; Berivan Baskin; Maria Isabel W Achatz; Dimitrios J Stavropoulos; Kim E Nichols; Louanne Hudgins; Chantal F Morel; Margaret P Adam; Nataliya Zhukova; Lianne Rotin; Ana Novokmet; Harriet Druker; Mary Shago; Peter N Ray; Pierre Hainaut; David Malkin
Journal:  Am J Hum Genet       Date:  2010-11-12       Impact factor: 11.025

3.  A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.

Authors:  Huayi Li; Wenxin Zhang; Kunming Zhao; Dong Zhao; Shanliang Zheng; Ying Hu
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

4.  Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.

Authors:  Houda Saadi; Marion Seillier; Maria José Sandi; Sylvain Peuget; Christine Kellenberger; Gwenaëlle Gravis; Nelson J Dusetti; Juan L Iovanna; Palma Rocchi; Mohamed Amri; Alice Carrier
Journal:  Results Immunol       Date:  2013-05-28

5.  Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Authors:  Marco M Candeias; Masatoshi Hagiwara; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

6.  Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.

Authors:  Qian Wu; Hua Qin; Qiu Zhao; Xing-Xing He
Journal:  Biomed Rep       Date:  2015-06-11

Review 7.  Regulation of tumor suppressor p53 at the RNA level.

Authors:  Anna Vilborg; Margareta T Wilhelm; Klas G Wiman
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

Review 8.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

9.  Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Sicong Lu; Zhiwei Chen; Guangzhi Zhu; Hao Su; Zengnan Mo; Xue Qin; Tao Peng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

10.  Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.

Authors:  Long Lv; Ping Wang; Xiaoqing Zhou; Beicheng Sun
Journal:  Tumour Biol       Date:  2013-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.